UPClytics
View all cases

UPC APP 24524/2025

EP2493466 · NOVEL ANTITUMORAL USE OF CABAZITAXEL

Case details
Status
—
Action
Procedural application
Category
Case management orders
Parties
Claimants
Representatives
Respondents
Representatives
Division
Munich LD
Technology
  • Chemistry
    Pharmaceuticals
Language
—
First decided
Jun 27, 2025
EPO Opposition
How this compares
How long the court takes to reach a first decision.
Median days to first decision
All UPC124
Munich LDLocked
Judge Matthias ZigannLocked
Judge Alima ZanaLocked
Judge Tobias PichlmaierLocked
Judge Carola WagnerLocked

At the UPC: Sanofi Group (33 cases)·Zentiva Group (15 cases)

This dispute contains 6 other proceedings

UPC CoA 24/2026·UPC CFI 98/2026·UPC CFI 148/2024·CC 49716/2024·UPC APP 54972/2024 and 1 more

12 other defendants litigating the same or a related patent

UPC CoA 22/2026·UPC CoA 23/2026·UPC CoA 25/2026·UPC CoA 26/2026·UPC CoA 27/2026 and 7 more

Start a free trial to see how each one ended.

More cases: Munich LD·2025

Decisions
  • 2025-06-27
    Application RoP 333Public

    Summary: Procedural order from the Munich Local Division (UPC_CFI_148/2024 and UPC_CFI_503/2024) on Zentiva's application under R. 333 RoP for panel review of the judge-rapporteur's case management order of 8 May 2025 in Sanofi's infringement action concerning EP 2 493 466. The full panel reviewed how preliminary objections should be handled and the timetable for subsequent proceedings.

    Show the legal issues (3)
    • Panel review of judge-rapporteur order (R. 333 RoP)
    • Preliminary objections
    • Case management
Documents
  • A018985EE4166E1B463B5DBA248BD157_en.pdf2025-06-27EN